With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.Determining the true drivers and toxic species in protein misfolding diseases. Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.